© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
David R. Gandara, MD, director, Thoracic Oncology Program, and professor, UC Davis Comprehensive Cancer Center, discusses the combination of CTLA-4 agents with PD-1 and PD-L1 agents for the treatment of lung cancer.